ID   NALP1_HUMAN             Reviewed;        1473 AA.
AC   Q9C000; Q9BZZ8; Q9BZZ9; Q9HAV8; Q9UFT4; Q9Y2E0;
DT   18-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   21-MAR-2012, entry version 126.
DE   RecName: Full=NACHT, LRR and PYD domains-containing protein 1;
DE   AltName: Full=Caspase recruitment domain-containing protein 7;
DE   AltName: Full=Death effector filament-forming ced-4-like apoptosis protein;
DE   AltName: Full=Nucleotide-binding domain and caspase recruitment domain;
GN   Name=NLRP1; Synonyms=CARD7, DEFCAP, KIAA0926, NAC, NALP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS HIS-155; SER-246;
RP   MET-878; VAL-1119; VAL-1184; LEU-1241 AND CYS-1366.
RX   MEDLINE=21169419; PubMed=11270363; DOI=10.1038/sj.cdd.4400774;
RA   Bertin J., DiStefano P.S.;
RT   "The PYRIN domain: a novel motif found in apoptosis and inflammation
RT   proteins.";
RL   Cell Death Differ. 7:1273-1274(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   MEDLINE=21148093; PubMed=11250163; DOI=10.1016/S0960-9822(01)00056-2;
RA   Martinon F., Hofmann K., Tschopp J.;
RT   "The pyrin domain: a possible member of the death domain-fold family
RT   implicated in apoptosis and inflammation.";
RL   Curr. Biol. 11:R118-R120(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND MUTAGENESIS OF
RP   LYS-340.
RC   TISSUE=Erythroleukemia;
RX   MEDLINE=21153743; PubMed=11076957; DOI=10.1074/jbc.M009853200;
RA   Hlaing T., Guo R.-F., Dilley K.A., Loussia J.M., Morrish T.A.,
RA   Shi M.M., Vincenz C., Ward P.A.;
RT   "Molecular cloning and characterization of DEFCAP-L and -S, two
RT   isoforms of a novel member of the mammalian Ced-4 family of apoptosis
RT   proteins.";
RL   J. Biol. Chem. 276:9230-9238(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), AND INTERACTION
RP   WITH CASP2 AND CASP9.
RC   TISSUE=T-cell;
RX   MEDLINE=21153744; PubMed=11113115; DOI=10.1074/jbc.M006309200;
RA   Chu Z.-L., Pio F., Xie Z., Welsh K., Krajewska M., Krajewski S.,
RA   Godzik A., Reed J.C.;
RT   "A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-
RT   dependent caspase activation and apoptosis.";
RL   J. Biol. Chem. 276:9239-9245(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   MEDLINE=99246063; PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 282-1473 (ISOFORM 1), AND
RP   VARIANT VAL-1184.
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   FUNCTION, AND IDENTIFICATION IN NALP1 INFLAMMASOME COMPLEX.
RX   PubMed=12191486; DOI=10.1016/S1097-2765(02)00599-3;
RA   Martinon F., Burns K., Tschopp J.;
RT   "The inflammasome: a molecular platform triggering activation of
RT   inflammatory caspases and processing of proIL-beta.";
RL   Mol. Cell 10:417-426(2002).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=15285719; DOI=10.1042/BJ20040867;
RA   Sanz C., Calasanz M.J., Andreu E., Richard C., Prosper F.,
RA   Fernandez-Luna J.L.;
RT   "NALP1 is a transcriptional target for cAMP-response-element-binding
RT   protein (CREB) in myeloid leukaemia cells.";
RL   Biochem. J. 384:281-286(2004).
RN   [9]
RP   FUNCTION, AND MUTAGENESIS OF 339-GLY-LYS-340.
RX   PubMed=15212762; DOI=10.1016/j.cellsig.2004.02.006;
RA   Liu F., Lo C.F., Ning X., Kajkowski E.M., Jin M., Chiriac C.,
RA   Gonzales C., Naureckiene S., Lock Y.-W., Pong K., Zaleska M.M.,
RA   Jacobsen J.S., Silverman S., Ozenberger B.A.;
RT   "Expression of NALP1 in cerebellar granule neurons stimulates
RT   apoptosis.";
RL   Cell. Signal. 16:1013-1021(2004).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17164409; DOI=10.1369/jhc.6A7101.2006;
RA   Kummer J.A., Broekhuizen R., Everett H., Agostini L., Kuijk L.,
RA   Martinon F., van Bruggen R., Tschopp J.;
RT   "Inflammasome components NALP 1 and 3 Show distinct but separate
RT   Expression profiles in human tissues suggesting a site-specific role
RT   in the inflammatory response.";
RL   J. Histochem. Cytochem. 55:443-452(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=17349957; DOI=10.1016/j.molcel.2007.01.032;
RA   Faustin B., Lartigue L., Bruey J.-M., Luciano F., Sergienko E.,
RA   Bailly-Maitre B., Volkmann N., Hanein D., Rouiller I., Reed J.C.;
RT   "Reconstituted NALP1 inflammasome reveals two-step mechanism of
RT   caspase-1 activation.";
RL   Mol. Cell 25:713-724(2007).
RN   [12]
RP   STRUCTURE BY NMR OF 1-93.
RX   PubMed=14527388; DOI=10.1016/j.str.2003.08.009;
RA   Hiller S., Kohl A., Fiorito F., Herrmann T., Wider G., Tschopp J.,
RA   Gruetter M.G., Wuethrich K.;
RT   "NMR structure of the apoptosis- and inflammation-related NALP1 pyrin
RT   domain.";
RL   Structure 11:1199-1205(2003).
RN   [13]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO VITILIGO AND VITILIGO-ASSOCIATED
RP   AUTOIMMUNE DISEASES, AND VARIANT HIS-155.
RX   PubMed=17377159; DOI=10.1056/NEJMoa061592;
RA   Jin Y., Mailloux C.M., Gowan K., Riccardi S.L., LaBerge G.,
RA   Bennett D.C., Fain P.R., Spritz R.A.;
RT   "NALP1 in vitiligo-associated multiple autoimmune disease.";
RL   N. Engl. J. Med. 356:1216-1225(2007).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1371-1467.
RG   Northeast structural genomics consortium (NESG);
RT   "Northeast structural genomics consortium target HR3486E.";
RL   Submitted (OCT-2009) to the PDB data bank.
CC   -!- FUNCTION: Able to form cytoplasmic structures termed death
CC       effector filaments. Enhances APAF1 and cytochrome c-dependent
CC       activation of pro-caspase-9 and consecutive apoptosis. Stimulates
CC       apoptosis through activation of caspase-3. Involved in activation
CC       of caspase-1 and caspase-5 as part of the NALP1 inflammasome
CC       complex which leads to processing and release of IL1B and IL18.
CC       Binds ATP.
CC   -!- SUBUNIT: Interacts strongly with caspase-2, weakly with caspase-9
CC       and with APAF1 in a cytochrome c-inducible way, leading to the
CC       formation of an apoptosome. This interaction may be ATP-dependent.
CC       Part of the NALP1 inflammasome complex which is involved in
CC       activation of caspase-1 and caspase-5, leading to processing of
CC       IL1B and IL18. The complex is activated by bacterial muramyl
CC       dipeptide which triggers ATP-binding and oligomerization of NALP1.
CC   -!- INTERACTION:
CC       P10415:BCL2; NbExp=12; IntAct=EBI-1220518, EBI-77694;
CC       Q07817:BCL2L1; NbExp=9; IntAct=EBI-1220518, EBI-78035;
CC       Q9ULZ3:PYCARD; NbExp=5; IntAct=EBI-1220518, EBI-751215;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=NAC beta, DEFCAP-L;
CC         IsoId=Q9C000-1; Sequence=Displayed;
CC       Name=2; Synonyms=NAC alpha, DEFCAP-S;
CC         IsoId=Q9C000-2; Sequence=VSP_004327;
CC       Name=3; Synonyms=NAC gamma;
CC         IsoId=Q9C000-3; Sequence=VSP_004326, VSP_004327;
CC       Name=4; Synonyms=NAC delta;
CC         IsoId=Q9C000-4; Sequence=VSP_004326;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 and isoform 2 are
CC       expressed in peripheral blood leukocytes and chronic myelogenous
CC       leukemia cell line K-562, followed by thymus, spleen and heart.
CC       Also detected in brain, lung, placenta, small intestine, colon,
CC       kidney, liver, muscle, testis and epithelial cells. Absent from
CC       hematopoietic progenitor cells but expressed upon differentiation
CC       of cells into granulocytes and, to a lesser extent, monocytes. In
CC       peripheral blood cells, highest levels are found in T-lymphocytes,
CC       granulocytes and monocytes. Expression is significantly increased
CC       in bone marrow blast cells of some acute leukemia patients but not
CC       in solid tumors.
CC   -!- DISEASE: Genetic variations in NLRP1 are associated with
CC       susceptibility to vitiligo (VTLG) [MIM:193200]. VTLG is a
CC       pigmentary disorder of the skin characterized by circumscribed
CC       depigmented macules and patches, commonly on extensor aspects of
CC       extremities, on the face or neck and in skin folds. It is a
CC       progressive disorder in which some or all of the melanocytes in
CC       the affected skin are selectively destroyed. It is a
CC       multifactorial disorder with a complex etiology probably including
CC       autoimmune mechanisms, and is associated with an elevated risk of
CC       other autoimmune diseases.
CC   -!- DISEASE: Genetic variations in NLRP1 gene are associated with
CC       susceptibility to vitiligo-associated multiple autoimmune disease
CC       type 1 (VAMAS1) [MIM:606579]. VAMAS1 is an autoimmune disorder
CC       characterized by the association of vitiligo with several
CC       autoimmune and autoinflammatory diseases including autoimmune
CC       thyroid disease, rheumatoid arthritis and systemic lupus
CC       erythematosus.
CC   -!- SIMILARITY: Belongs to the NLRP family.
CC   -!- SIMILARITY: Contains 1 CARD domain.
CC   -!- SIMILARITY: Contains 1 DAPIN domain.
CC   -!- SIMILARITY: Contains 6 LRR (leucine-rich) repeats.
CC   -!- SIMILARITY: Contains 1 NACHT domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA76770.2; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF298548; AAG15254.1; -; mRNA.
DR   EMBL; AF310105; AAG30288.1; -; mRNA.
DR   EMBL; AF229059; AAK00748.1; -; mRNA.
DR   EMBL; AF229060; AAK00749.1; -; mRNA.
DR   EMBL; AF229061; AAK00750.1; -; mRNA.
DR   EMBL; AF229062; AAK00751.1; -; mRNA.
DR   EMBL; AB023143; BAA76770.2; ALT_INIT; mRNA.
DR   EMBL; AL117470; CAB55945.1; -; mRNA.
DR   IPI; IPI00004551; -.
DR   IPI; IPI00099688; -.
DR   IPI; IPI00328123; -.
DR   IPI; IPI00335800; -.
DR   PIR; T17255; T17255.
DR   RefSeq; NP_001028225.1; NM_001033053.2.
DR   RefSeq; NP_055737.1; NM_014922.4.
DR   RefSeq; NP_127497.1; NM_033004.3.
DR   RefSeq; NP_127499.1; NM_033006.3.
DR   RefSeq; NP_127500.1; NM_033007.3.
DR   UniGene; Hs.652273; -.
DR   PDB; 1PN5; NMR; -; A=1-93.
DR   PDB; 3KAT; X-ray; 3.10 A; A=1371-1467.
DR   PDBsum; 1PN5; -.
DR   PDBsum; 3KAT; -.
DR   ProteinModelPortal; Q9C000; -.
DR   SMR; Q9C000; 1-93, 784-985, 1322-1463.
DR   DIP; DIP-38407N; -.
DR   IntAct; Q9C000; 8.
DR   STRING; Q9C000; -.
DR   DMDM; 17380146; -.
DR   PRIDE; Q9C000; -.
DR   DNASU; 22861; -.
DR   Ensembl; ENST00000269280; ENSP00000269280; ENSG00000091592.
DR   GeneID; 22861; -.
DR   KEGG; hsa:22861; -.
DR   UCSC; uc002gch.2; human.
DR   UCSC; uc002gci.1; human.
DR   UCSC; uc002gcj.1; human.
DR   UCSC; uc002gcl.1; human.
DR   CTD; 22861; -.
DR   GeneCards; GC17M005407; -.
DR   H-InvDB; HIX0013474; -.
DR   HGNC; HGNC:14374; NLRP1.
DR   HPA; CAB009189; -.
DR   MIM; 193200; phenotype.
DR   MIM; 606579; phenotype.
DR   MIM; 606636; gene.
DR   neXtProt; NX_Q9C000; -.
DR   Orphanet; 3435; Vitiligo.
DR   PharmGKB; PA162397797; -.
DR   eggNOG; NOG146295; -.
DR   GeneTree; ENSGT00650000093077; -.
DR   HOGENOM; HBG282263; -.
DR   HOVERGEN; HBG052573; -.
DR   InParanoid; Q9C000; -.
DR   KO; K12798; -.
DR   OMA; PHLIMEL; -.
DR   Pathway_Interaction_DB; anthraxpathway; Cellular roles of Anthrax toxin.
DR   Reactome; REACT_6900; Immune System.
DR   NextBio; 43357; -.
DR   ArrayExpress; Q9C000; -.
DR   Bgee; Q9C000; -.
DR   CleanEx; HS_NLRP1; -.
DR   Genevestigator; Q9C000; -.
DR   GermOnline; ENSG00000091592; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0072558; C:NLRP1 inflammasome complex; TAS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0008656; F:cysteine-type endopeptidase activator activity involved in apoptotic process; NAS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:BHF-UCL.
DR   GO; GO:0006917; P:induction of apoptosis; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0051402; P:neuron apoptosis; IDA:HGNC.
DR   GO; GO:0035872; P:nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; ISS:BHF-UCL.
DR   GO; GO:0050727; P:regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032495; P:response to muramyl dipeptide; ISS:BHF-UCL.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR004020; DAPIN.
DR   InterPro; IPR011029; DEATH-like.
DR   InterPro; IPR000767; Disease_R.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   Gene3D; G3DSA:1.10.533.10; DEATH_like; 2.
DR   Pfam; PF00619; CARD; 1.
DR   Pfam; PF02758; PYRIN; 1.
DR   PRINTS; PR00364; DISEASERSIST.
DR   SUPFAM; SSF47986; DEATH_like; 2.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS50824; DAPIN; 1.
DR   PROSITE; PS51450; LRR; 3.
DR   PROSITE; PS50837; NACHT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Complete proteome; Cytoplasm; Leucine-rich repeat; Nucleotide-binding;
KW   Nucleus; Polymorphism; Reference proteome; Repeat.
FT   CHAIN         1   1473       NACHT, LRR and PYD domains-containing
FT                                protein 1.
FT                                /FTId=PRO_0000096710.
FT   DOMAIN        1     92       DAPIN.
FT   DOMAIN      328    637       NACHT.
FT   REPEAT      809    830       LRR 1.
FT   REPEAT      838    858       LRR 2.
FT   REPEAT      866    887       LRR 3.
FT   REPEAT      895    915       LRR 4.
FT   REPEAT      923    944       LRR 5.
FT   REPEAT      950    973       LRR 6.
FT   DOMAIN     1374   1463       CARD.
FT   NP_BIND     334    341       ATP (Potential).
FT   VAR_SEQ     958    987       Missing (in isoform 3 and isoform 4).
FT                                /FTId=VSP_004326.
FT   VAR_SEQ    1262   1305       Missing (in isoform 2 and isoform 3).
FT                                /FTId=VSP_004327.
FT   VARIANT     155    155       L -> H (associated with susceptibility to
FT                                vitiligo and vitiligo-associated
FT                                autoimmune diseases; dbSNP:rs12150220).
FT                                /FTId=VAR_033239.
FT   VARIANT     246    246       T -> S (in dbSNP:rs11651595).
FT                                /FTId=VAR_024238.
FT   VARIANT     404    404       R -> Q (in dbSNP:rs3744718).
FT                                /FTId=VAR_021886.
FT   VARIANT     878    878       T -> M (in dbSNP:rs11657747).
FT                                /FTId=VAR_033240.
FT   VARIANT    1059   1059       V -> M (in dbSNP:rs2301582).
FT                                /FTId=VAR_024239.
FT   VARIANT    1069   1069       H -> Y (in dbSNP:rs9907167).
FT                                /FTId=VAR_033241.
FT   VARIANT    1119   1119       M -> V (in dbSNP:rs35596958).
FT                                /FTId=VAR_033242.
FT   VARIANT    1184   1184       M -> V (in dbSNP:rs11651270).
FT                                /FTId=VAR_033243.
FT   VARIANT    1241   1241       V -> L (in dbSNP:rs11653832).
FT                                /FTId=VAR_033244.
FT   VARIANT    1366   1366       R -> C (in dbSNP:rs2137722).
FT                                /FTId=VAR_020437.
FT   MUTAGEN     339    340       GK->EA: Abolishes binding to ATP.
FT   MUTAGEN     340    340       K->L,S: No effect.
FT   CONFLICT    782    782       T -> S (in Ref. 1; AAG15254).
FT   CONFLICT    995    995       T -> I (in Ref. 1; AAG15254).
FT   HELIX         9     15
FT   HELIX        18     31
FT   HELIX        50     60
FT   HELIX        63     77
FT   HELIX        80     85
FT   STRAND       88     91
SQ   SEQUENCE   1473 AA;  165866 MW;  438F0DCE45C2562D CRC64;
     MAGGAWGRLA CYLEFLKKEE LKEFQLLLAN KAHSRSSSGE TPAQPEKTSG MEVASYLVAQ
     YGEQRAWDLA LHTWEQMGLR SLCAQAQEGA GHSPSFPYSP SEPHLGSPSQ PTSTAVLMPW
     IHELPAGCTQ GSERRVLRQL PDTSGRRWRE ISASLLYQAL PSSPDHESPS QESPNAPTST
     AVLGSWGSPP QPSLAPREQE APGTQWPLDE TSGIYYTEIR EREREKSEKG RPPWAAVVGT
     PPQAHTSLQP HHHPWEPSVR ESLCSTWPWK NEDFNQKFTQ LLLLQRPHPR SQDPLVKRSW
     PDYVEENRGH LIEIRDLFGP GLDTQEPRIV ILQGAAGIGK STLARQVKEA WGRGQLYGDR
     FQHVFYFSCR ELAQSKVVSL AELIGKDGTA TPAPIRQILS RPERLLFILD GVDEPGWVLQ
     EPSSELCLHW SQPQPADALL GSLLGKTILP EASFLITART TALQNLIPSL EQARWVEVLG
     FSESSRKEYF YRYFTDERQA IRAFRLVKSN KELWALCLVP WVSWLACTCL MQQMKRKEKL
     TLTSKTTTTL CLHYLAQALQ AQPLGPQLRD LCSLAAEGIW QKKTLFSPDD LRKHGLDGAI
     ISTFLKMGIL QEHPIPLSYS FIHLCFQEFF AAMSYVLEDE KGRGKHSNCI IDLEKTLEAY
     GIHGLFGAST TRFLLGLLSD EGEREMENIF HCRLSQGRNL MQWVPSLQLL LQPHSLESLH
     CLYETRNKTF LTQVMAHFEE MGMCVETDME LLVCTFCIKF SRHVKKLQLI EGRQHRSTWS
     PTMVVLFRWV PVTDAYWQIL FSVLKVTRNL KELDLSGNSL SHSAVKSLCK TLRRPRCLLE
     TLRLAGCGLT AEDCKDLAFG LRANQTLTEL DLSFNVLTDA GAKHLCQRLR QPSCKLQRLQ
     LVSCGLTSDC CQDLASVLSA SPSLKELDLQ QNNLDDVGVR LLCEGLRHPA CKLIRLGLDQ
     TTLSDEMRQE LRALEQEKPQ LLIFSRRKPS VMTPTEGLDT GEMSNSTSSL KRQRLGSERA
     ASHVAQANLK LLDVSKIFPI AEIAEESSPE VVPVELLCVP SPASQGDLHT KPLGTDDDFW
     GPTGPVATEV VDKEKNLYRV HFPVAGSYRW PNTGLCFVMR EAVTVEIEFC VWDQFLGEIN
     PQHSWMVAGP LLDIKAEPGA VEAVHLPHFV ALQGGHVDTS LFQMAHFKEE GMLLEKPARV
     ELHHIVLENP SFSPLGVLLK MIHNALRFIP VTSVVLLYHR VHPEEVTFHL YLIPSDCSIR
     KAIDDLEMKF QFVRIHKPPP LTPLYMGCRY TVSGSGSGML EILPKELELC YRSPGEDQLF
     SEFYVGHLGS GIRLQVKDKK DETLVWEALV KPGDLMPATT LIPPARIAVP SPLDAPQLLH
     FVDQYREQLI ARVTSVEVVL DKLHGQVLSQ EQYERVLAEN TRPSQMRKLF SLSQSWDRKC
     KDGLYQALKE THPHLIMELW EKGSKKGLLP LSS
//
